Drug Profile
Research programme: cancer immunotherapeutics - Sumitomo Pharma
Alternative Names: SMP-105Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Sumitomo Pharma
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer